Tigecycline activity tested against 11 808 bacterial pathogens recently collected from US medical centers

Diagnostic Microbiology and Infectious Disease

Volumn 60, Issue 4, 2008, Pages 421-427

  Gales, Ana C ^a   Sader, Helio S ^a,b   Fritsche, Thomas R ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b JMI LABORATORIES   (United States)

Author keywords

Antimicrobial activity; Drug microbial resistance; North America; Surveillance; Tigecycline

Indexed keywords

ANTIINFECTIVE AGENT; GLYCYLCYCLINE DERIVATIVE; IMIPENEM; LINEZOLID; PENICILLIN G; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL VIRULENCE; DRUG ACTIVITY; DRUG POTENCY; ENTEROCOCCUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; UNITED STATES;

EID: 40749142795     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2007.10.017     Document Type: Article

References (22)

1. Bauer G., Berens C., Projan S.J., and Hillen W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J. Antimicrob. Chemother. 53 (2004) 592-599
2. Bergeron J., Ammirati M., Danley D., James L., Norcia M., Retsema J., Strick C.A., Su W.G., Sutcliffe J., and Wondrack L. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob. Agents Chemother. 40 (1996) 2226-2228
3. Bouchillon S.K., Hoban D.J., Johnson B.M., Johnson J.L., Hsiung A., and Dowzicky M.J. In vitro activity of tigecycline against 3,989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn. Microbiol. Infect. Dis. 52 (2005) 173-179
4. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved Standard, M7-A7. 7th ed. (2006), CLSI, Wayne, PA
5. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 17th Informational Supplement. M100-S17 (2007), CLSI, Wayne, PA
6. Curcio D., and Fernandez F. Acinetobacter spp. susceptibility to tigecycline: a worldwide perspective. J. Antimicrob. Chemother. 60 (2007) 449-450
7. Daly M.W., Riddle D.J., Ledeboer N.A., Dunne W.M., and Ritchie D.J. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy 27 (2007) 1052-1057
8. Deshpande L.M., Jones R.N., Fritsche T.R., and Sader H.S. Occurrence and characterization of carbapenemases produced by Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microb. Drug Resist. 12 (2006) 223-230
9. Fernandez-Mazarrasa C., Mazarrasa O., Calvo J., Del Arco A., and Martinez Martinez L. High Concentration of Manganese in Mueller-Hinton Agar Increase MICs of Tigecycline Determined by Etest. Abstr. D-227. 47th ICAAC (2007) 154 [Chicago]
10. Fritsche T.R., Sader H.S., Stilwell M.G., Dowzicky M.J., and Jones R.N. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn. Microbiol. Infect. Dis. 52 (2005) 187-193
11. Fritsche T.R., Sader H.S., Stilwell M.G., Dowzicky M.J., and Jones R.N. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn. Microbiol. Infect. Dis. 52 (2005) 195-201
12. Hawkey P., and Finch R. Tigecycline: in-vitro performance as a predictor of clinical efficacy. Clin. Microbiol. Infect. 13 (2007) 354-362
13. Hoban D.J., Bouchillon S.K., Johnson B.M., Johnson J.L., and Dowzicky M.J. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn. Microbiol. Infect. Dis. 52 (2005) 215-227
14. Jones R.N., Ferraro M.J., Reller L.B., Schreckenberger P.C., Swenson J.M., and Sader H.S. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J. Clin. Microbiol. 45 (2007) 227-230
15. Jones R.N., Mendes C., Turner P.J., and Masterton R. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004. Diagn. Microbiol. Infect. Dis. 53 (2005) 247-256
16. Koeth L.M., and Miller L.A. Evolving concepts of pharmaceutical company-sponsored surveillance studies. Clin. Infect. Dis. 41 Suppl. 4 (2005) S279-S282
17. Navon-Venezia S., Leavitt A., and Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 59 (2007) 772-774
18. Petersen P.J., and Bradford P.A. Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob. Agents Chemother. 49 (2005) 3910-3918
19. Petersen P.J., Jacobus N.V., Weiss W.J., Sum P.E., and Testa R.T. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43 (1999) 738-744
20. Sader H.S., Jones R.N., Dowzicky M.J., and Fritsche T.R. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn. Microbiol. Infect. Dis. 52 (2005) 203-208
21. Sader H.S., Jones R.N., Stilwell M.G., Dowzicky M.J., and Fritsche T.R. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn. Microbiol. Infect. Dis. 52 (2005) 181-186
22. Tygacil™ Package Insert (2005), Wyeth Pharmaceuticals Inc, Philadelphia, PA